Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, announ...
Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a pioneering oncology biopharmaceutical company, has revealed prom...
Approval based primarily on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placebo CSU is the fifth approved...
Mesoblast's Chief Executive, Silviu Itescu, expressed satisfaction with the FDA's decision: “We are very pleased to have now been granted both Orphan...
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a distinguished player in the clinical-stage biopharmaceutical arena, has achieved a significant milestone wit...
Takeda unveiled promising topline results from a comprehensive Phase 2b trial evaluating TAK-861, an oral orexin receptor 2 (OX2R) agonist, in patien...
Auron Therapeutics, a pioneering biotechnology firm dedicated to advancing targeted cancer therapies, has announced the selection of its in...
Medidata, a Dassault Systèmes company and a leading provider of clinical trial solutions to the life sciences industry, has joined forces with Sanof...
Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company ded...
Hummingbird Diagnostics GmbH, a leader in the analysis of blood-based small RNA (sRNA) for the early detection and characterization of diseases, today anno...
Zurletrectinib, developed by InnoCare, is a pan-TRK inhibitor which markedly inhibits the activity of the wild type TRKA, TRKB and TRKC, as well as mutant ...
Kairos Pharma CEO John Yu stated, “The initiation of this trial speaks to the dedication of the Kairos team to execute on its goals to develop therap...
Menarini Silicon Biosystems, a pioneer of liquid biopsy and single-cell technologies, announced the recent publication of the STIC CTC trial data demonstra...
The restructuring is intended to further reduce expenditures and enable greater concentration of company resources on a planned Phase 1 clinical trial for ...
© 2024 Biopharma Boardroom. All Rights Reserved.
